Top Markets
#1 MowCat MowCat +48.88%
#2 Bermuda Shorts Bermuda Shorts +25.27%
#3 Velvet Velvet +25.14%
#4 Derive Derive +21.09%
#5 Audiera Audiera +20.34%
#6 Biconomy Biconomy +18.91%
#7 aPriori aPriori +18.15%
#8 Quack AI Quack AI +17.54%
#9 Geodnet Geodnet +12.27%
#10 Perle Perle +10.44%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Tricida, Inc. Tricida, Inc.

Tricida, Inc.

TCDA
Rank in Stocks #35026
Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the... Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the advancement and market introduction of veverimer (TRC101). This compound, an orally ingested, non-systemic polymer, has successfully concluded its Phase III clinical trials. Veverimer is designed to address metabolic acidosis in individuals suffering from chronic kidney disease by specifically targeting and eliminating excess acid within the gastrointestinal tract. The company was established in 2013 and is headquartered in South San Francisco, California.
Share Price
$0.108
Last synced: 2023-01-23
Market Cap
$4.56M
Change (1 day)
-10.00%
Change (1 year)
0.00%
Country
US
Trade Tricida, Inc. (TCDA)

Category

Healthcare
Earnings for Tricida, Inc. (TCDA)
Earnings in 2026 TTM: 0
According to Tricida, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Tricida, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE